Glaucoma – new possibilities, new research Review article

Article Sidebar

PDF PDF (Język Polski)


Published: Mar 31, 2023
DOI: https://doi.org/10.24292/01.OT.200323.1
Keywords:
glaucoma, treatment, new drugs, new therapies, neuroprotection, gene therapy

Main Article Content

Dorota Szumny
1. Chair and Department of Pharmacology, Medical University of Wroclaw. 2. Department of Ophthalmology, University Clinical Hospital in Wroclaw
http://orcid.org/0000-0002-7814-3517
Małgorzata Mulak
1. Department of Ophthalmology, University Clinical Hospital in Wroclaw. 2. Department and Clinic of Ophthalmology, Wroclaw Medical University
http://orcid.org/0000-0003-3598-6693

Abstract

Research efforts to develop effective and safe antiglaucoma drugs have been ongoing for many years. The cornerstone of treatment is still baroprotection, as this is virtually the only method available to protect the optic nerve and slow glaucoma progression, which can be easily controlled by an ophthalmologist. Research is also being conducted in the direction of neuroprotection, where new compounds are being evaluated, as well as those that have been used for years as adjunctive treatments. The greatest hope lies in gene therapy, which still has many problems to be solved, but it is the only one that offers hope for the patient’s complete recovery.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Szumny D, Mulak M. Glaucoma – new possibilities, new research. Ophthatherapy [Internet]. 2023Mar.31 [cited 2024Apr.20];10(1):7-11. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/2742
Issue
Vol 10 No 1 (2023)
Section
Diagnostics
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Novack GD, Robin AL. Ocular pharmacology. J Clin Pharmacol. 2016; 56(5): 517-27.
2. Wierzbowska J. Terapie eksperymentalne w jaskrze. OphthaTherapy. 2014; 1(4): 239-45.
3. Szumny D. Nowe trendy w farmakoterapii jaskry. OphthaTherapy. 2019; 6(1): 26-9.
4. Kusuhara S, Nakamura M. Ripasudil hydrochloride hydrate in the treatment of glaucoma: safety, efficacy, and patient selection. Clin Ophthalmol. 2020;14: 1229-36.
5. Li G, Torrejon KY, Unser AM et al. Trabodenoson, an adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice. Invest Ophthalmol Vis Sci. 2018; 59(1): 383-92.
6. Clinicaltrials.gov. Glaucoma [online].
7. Amador C, Shah R, Ghiam S et al. Gene therapy in the anterior eye segment. Curr Gene Ther. 2022; 22(2): 104-31.
8. Miller PE, Eaton JS. Medical anti-glaucoma therapy: Beyond the drop. Vet Ophthalmol. 2021; 24(Suppl 1): 2-15.
9. Schuettauf F, Rejdak R, Thaler S et al. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp Eye Res. 2006; 83(5): 1128-34.
10. Matteucci A, Varano M, Gaddini L et al. Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration. Int J Mol Sci. 2014; 15(4): 6286-97.
11. He S, Stankowska DL, Ellis DZ et al. Targets of Neuroprotection in Glaucoma. J Ocul Pharmacol Ther. 2018; 34(1-2): 85-106.
12. Parisi V, Oddone F, Ziccardi L et al. Citicoline and retinal ganglion cells: effects on morphology and function. Curr Neuropharmacol. 2018; 16(7): 919-32.
13. Parisi V, Oddone F, Roberti G et al. Enhancement of retinal function and of neural conduction along the visual pathway induced by treatment with citicoline eye drops in liposomal formulation in open angle glaucoma: a pilot electrofunctional study. Adv Ther. 2019; 36: 987-96.
14. Rejdak R, Toczołowski J, Kurkowski J et al. Oral citicoline treatment improves visual pathway function in glaucoma. Medical Science Monitor. Med Sci Monit. 2003; 9(3): PI24-8.
15. Doozandeh A, Yazdani S. Neuroprotection in Glaucoma. J Ophthalmic Vis Res. 2016; 11(2): 209-20.
16. Smedowski A, Liu X, Podracka L et al. Increased intraocular pressure alters the cellular distribution of HuR protein in retinal ganglion cells–a possible sign of endogenous neuroprotection failure. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(1): 296-306.
17. Smedowski A, Liu X, Pietrucha-Dutczak M et al. Predegenerated Schwann cells–a novel prospect for cell therapy for glaucoma: neuroprotection, neuroregeneration and neuroplasticity. Sci Rep. 2016; 6(1): 23187.
18. Komáromy AM. Is Gene Therapy an Option for Glaucoma? [online].
19. Ross AG. Gene Therapy and Glaucoma: An Update [online].
20. Chern KJ, Nettesheim ER, Reid CA et al. Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats. Commun Biol. 2022; 5(1): 1169.
21. O’Callaghan J, Crosbie DE, Cassidy PS et al. Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Hum Mol Genet. 2017; 26(7): 1230-46.